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Abstract 
 
Deep learning architectures have proved versatile in a number of drug discovery applications, 
including the modelling of in vitro compound activity. While controlling for prediction confidence 
is essential to increase the trust, interpretability and usefulness of virtual screening models in 
drug discovery, techniques to estimate the reliability of the predictions generated with deep 
learning networks remain largely underexplored. Here, we present Deep Confidence, a 
framework to compute valid and efficient confidence intervals for individual predictions using the 
deep learning technique Snapshot Ensembling and conformal prediction. Specifically, Deep 
Confidence generates an ensemble of deep neural networks by recording the network 
parameters throughout the local minima visited during the optimization phase of a single neural 
network. This approach serves to derive a set of base learners (i.e., snapshots) with 
comparable predictive power on average, that will however generate slightly different 
predictions for a given instance. The variability across base learners and the validation residuals 
are in turn harnessed to compute confidence intervals using the conformal prediction 
framework. Using a set of 24 diverse IC50 data sets from ChEMBL 23, we show that Snapshot 
Ensembles perform on par with Random Forest (RF) and ensembles of independently trained 
deep neural networks. In addition, we find that the confidence regions predicted using the Deep 
Confidence framework span a narrower set of values. Overall, Deep Confidence represents a 
highly versatile error prediction framework that can be applied to any deep learning-based 
application at no extra computational cost.  
 
  
 3 
Introduction 
 
To date, a plethora of deep learning applications have been proposed to aid in multiple drug 
discovery tasks1–7, including de novo drug design8,9, automatic molecular design10, design of 
focused molecule libraries11, multi-target bioactivity prediction12–15, compound synergy 
modelling16, as well as compound property17, single-target bioactivity18–21 and toxicity 
prediction22, among others. Multiple studies have shown that deep neural networks (DNN) often  
outperform commonly used algorithms when applied to model in vitro bioactivity data, including 
Support Vector Machines (SVM) and Random Forests (RF)21,23,24. Importantly, the higher 
predictive power of deep learning has been shown for both large and small data sets13,19,20. 
Hence, DNN are becoming a standard technique to model in vitro compound activity1,25. 
 
Defining the set of molecules for which a model can generate reliable predictions has been (and 
still is26) an area of intense research because an accurate estimation of prediction errors is 
essential for a model to inform decision-making in drug discovery27–30. While diverse deep 
learning architectures have been developed to predict compound activity as point 
predictions12,18,23, modelling prediction uncertainty for small molecules using deep learning still 
remains an unexplored area, and this is precisely what we address in this contribution. 
 
Among the array of methods developed to compute the uncertainty of individual predictions, 
conformal prediction31,32 has been extensively applied in drug discovery over the last few years 
to model compound toxicity33, in vitro bioactivity data34–38, and to guide in silico iterative 
screening campaigns.39,40 A key advantage of conformal prediction is that each prediction is 
given as a confidence interval, that will be more or less stringent depending on the user-
selected confidence level (CL)31. Moreover, these predicted confidence regions are guaranteed 
to be valid by a solid mathematical foundation provided that the exchangeability principle is 
fulfilled, which is generally assumed to be the case when modelling bioactivity data31,32,36. The 
validity of a conformal predictor means that, at a user-defined CL, the measured error rate, i.e., 
the fraction of instances for which the true value lies outside the predicted region, will not be 
larger than the chosen error rate (i.e., 1 - CL). For instance, at a confidence level of 80%, at 
least 80% of the predicted confidence regions will contain the true value. Thus, in contrast to 
most other prediction error methods, which do not guarantee a lower bound for the fraction of 
the predictions that will be correct, conformal prediction is a very powerful technique in practice; 
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for instance, in a drug discovery project it permits to select compounds for further experimental 
testing while controlling for the fraction of instances whose experimentally measured bioactivity 
will be above a cut-off value of interest36,39,40. 
 
Another major advantage of conformal prediction is that, as opposed to e.g., Bayesian 
methods41–45, it requires little computational cost beyond the training of the underlying 
algorithms, no parameter optimization, and can be coupled to any machine learning algorithm36. 
In the deep learning community, previous work on estimating predictive uncertainty for DNN 
used both Bayesian and non-Bayesian approaches46–51. In addition, post-processing of the 
softmax layer, although it is not a measure of confidence52, has proved useful to deliver 
calibrated class probabilities in classification problems53,54. However, to the best of our 
knowledge, the integration of conformal prediction and deep learning to model bioactivity data 
has not been explored to date.  
 
Here, we propose Deep Confidence, a versatile and computationally efficient framework to 
compute confidence intervals for individual predictions. Deep Confidence leverages the key 
advantages of both deep learning and conformal prediction, and can be easily integrated into 
any deep learning architecture. Deep Confidence uses Snapshot Ensembles55 to generate an 
ensemble of DNN from the training of a single DNN. To generate a Snapshot Ensemble, 
intermediate states of a DNN during the optimization path of its parameters are taken (Figure 1). 
The main advantage of Snapshot Ensembles is that these snapshots are ‘free’, given that no 
extra computation is required to generate them beyond the computation time needed to train the 
network. The training phase is divided into cycles, throughout which the learning rate is 
annealed and set back to its original value at the beginning of the next cycle. At the end of a 
cycle, the current state of the DNN is used as a base learner in the Snapshot Ensemble 
provided that the DNN has (sufficiently) converged to a local minimum during that cycle. 
Convergence is measured using the loss on the validation set, which in the current study was 
the Root Mean Squared Error (RMSE) in prediction. A cut-off value related to the uncertainty of 
the data at hand can be used to dismiss snapshots with low predictive power before the network 
starts converging; for instance, 1.2 pIC50 units, which corresponds to about two times the 
experimental uncertainty of public heterogeneous IC50 data56,57. Therefore, while the average 
error in prediction might be similar across snapshots, the predictions for a given instance 
calculated by each snapshot will be different55. The fact that the snapshot predictions are 
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correlated but not identical adds sufficient diversity to generate an ensemble with high predictive 
power58. Once the Snapshot Ensemble has been generated, the predictions of each snapshot 
on the validation and test sets are used to generate a conformal predictor.  
 
We here show using 24 diverse bioactivity data sets from ChEMBL version 23 (Table 1) that 
Deep Confidence generates valid confidence intervals, and that these span a narrower range of 
values than those calculated using RF-based conformal predictors while leading to a 
comparable average interval size. In addition, we show that Snapshot Ensembles and 
ensembles of independently trained DNN lead to comparable predictive power on unseen data 
during the training phase. Thus, Deep Confidence represents a versatile approach to model 
bioactivity data using DNN ensembles at a vastly reduced computing cost while also providing 
an estimation of the reliability of individual predictions. 
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Methods 
 
Data Sets 
We gathered IC50 data for 24 diverse protein targets and receptors from the ChEMBL database 
version 23 using the chembl_webresource_client python module59–61. Only IC50 values for small 
molecules that satisfied the following filtering criteria were retained: (i) an activity unit equal to 
“nM”, (ii) activity relationship equal to ‘=’, (iii) target type equal to “SINGLE PROTEIN”, and (iv) 
organism equal to Homo sapiens. IC50 values were modeled in a logarithmic scale (pIC50 = 
−log10 IC50). The average pIC50 value was calculated when multiple pIC50 values were available 
for the same compound. Further information about the data sets is given in Table 1 and in 62. All 
data sets are provided in the Supporting Information. 
 
Table 1. Data sets used in this study. 
Target preferred name 
Target 
abbreviation 
Uniprot 
ID 
ChEMBL ID 
Number of 
bioactivity data 
points 
Alpha-2a adrenergic 
receptor 
A2a P08913 CHEMBL1867 203 
Tyrosine-protein kinase ABL ABL1 P00519 CHEMBL1862 773 
Acetylcholinesterase 
Acetylcholinester
ase 
P22303 CHEMBL220 3,159 
Serine/threonine-protein 
kinase Aurora-A 
Aurora-A O14965 CHEMBL4722 2,125 
Serine/threonine-protein 
kinase B-raf 
B-raf P15056 CHEMBL5145 1,730 
Cannabinoid CB1 receptor Cannabinoid P21554 CHEMBL218 1,116 
Carbonic anhydrase II Carbonic P00918 CHEMBL205 603 
Caspase-3 Caspase P42574 CHEMBL2334 1,606 
Thrombin Coagulation P00734 CHEMBL204 1,700 
Cyclooxygenase-1 COX-1 P23219 CHEMBL221 1,343 
Cyclooxygenase-2 COX-2 P35354 CHEMBL230 2,855 
Dihydrofolate reductase Dihydrofolate P00374 CHEMBL202 584 
Dopamine D2 receptor Dopamine P14416 CHEMBL217 479 
Norepinephrine transporter Ephrin P23975 CHEMBL222 1,740 
Epidermal growth factor 
receptor erbB1 
erbB1 P00533 CHEMBL203 4,868 
Estrogen receptor alpha Estrogen P03372 CHEMBL206 1,705 
Glucocorticoid receptor Glucocorticoid P04150 CHEMBL2034 1,447 
Glycogen synthase kinase-3 
beta 
Glycogen P49841 CHEMBL262 1,757 
HERG HERG Q12809 CHEMBL240 5,207 
Tyrosine-protein kinase 
JAK2 
JAK2 O60674 CHEMBL2971 2,655 
Tyrosine-protein kinase LCK LCK P06239 CHEMBL258 1,352 
Monoamine oxidase A Monoamine P21397 CHEMBL1951 1,379 
Mu opioid receptor Opioid P35372 CHEMBL233 840 
Vanilloid receptor Vanilloid Q8NER1 CHEMBL4794 1,923 
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Molecular Representation 
We standardized all chemical structures to a common representation scheme using the python 
module standardizer (https://github.com/flatkinson/standardiser). Inorganic molecules were 
removed, and the largest fragment was kept in order to filter out counterions. We next computed 
circular Morgan fingerprints63 for all compounds using RDkit (release version 2013.03.02)64. The 
radius was set to 2 and the fingerprint length to 128. In contrast to previous work65–67, we 
observed that longer fingerprints (256, 512 and 1024 bits) led to marginal increases in predictive 
power, and hence, we used 128 bits to reduce training times. 
 
Machine Learning 
In the following subsections, we explain the training procedures of the 5 learning strategies 
explored in this study and how conformal predictors were generated for each of them. For each 
training strategy and data set pair 20 repeats were performed, each time randomly assigning 
different sets of data points to the training, validation and test sets.  
 
- Deep Neural Networks (DNN) 
DNN were trained using the python library Pytorch68. The RMSE value on the validation set was 
used as the loss function during the training of all DNNs reported here. We defined three hidden 
layers, composed of 60, 20, and 10 nodes, respectively, and used rectified linear unit (ReLU) 
activation. We decided to use ReLU activation following previous work where higher predictive 
power was obtained with ReLU as compared to the Tanh and Sigmoid functions18. We set the 
number of nodes in each layer below the number of dimensions of the input data, i.e. 128, to 
reduce the risk of overfitting69.  
 
The data sets were randomly split into a training set (70% of the data), a validation set (15%), 
and a test set (15%). For each data set, the training set was used to train a given network, 
whereas the validation set served to monitor the performance of the network during the training 
phase. The training data were processed in batches of size equal to 15% of the number of 
instances, as using larger batches during training decreases the generalization ability of the 
models70. The test set was used to assess the generalization capabilities of the models on 
unseen data during the training phase.  
 
We used stochastic gradient descent with Nesterov momentum, which was set to 0.9 and kept 
constant during the training phase71. We allowed the networks to evolve over 3,000 epochs. To 
avoid overfitting we used early stopping, i.e., the training of a given network was stopped if the 
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validation loss did not decrease after 200 epochs. In addition, we used 10% dropout in the three 
hidden layers13,18,72. The DNN described in the following sections were trained using the 
parameter values and data partitions described above unless otherwise stated. 
 
- Ensembles of Deep Neural Networks  
We considered 2 strategies to generate ensembles of DNNs. Each ensemble encompassed 100 
DNN as base learners, each of them trained using the same validation and training sets. The 
point prediction for a given instance was calculated as the mean value of the 100 individual 
predictions.  
 
Ensembles of Independently Trained Deep Neural Networks (DNN Ensemble). The base 
learners in this case were 100 DNN independently trained using the same deep learning 
architecture. This corresponds to training the same type of DNN on the same training data, 
using different seed values at the start of the training phase. DNNs that failed to converge to 
RMSE values on the validation set smaller than 1.2 pIC50 units were discarded and not 
considered in the ensemble. After reaching convergence in the training phase, each DNN was 
used to predict the activity for both the validation and test sets. The learning rate was initially set 
to 0.005, and was decreased by 40% every 200 epochs. 
 
Snapshot Ensembles with learning rate annealing (Snapshot Ensemble Lr Annealing). 
Snapshot Ensembles were constructed by recording DNN snapshots55 during the training phase 
of a single DNN. This allows to generate multiple models, each corresponding to a different 
local minimum, while only training one DNN55. Each of these snapshots served as a base 
learner to generate a given Snapshot Ensemble (Figure 1 and 2). Early stopping was not used 
in this case. The learning rate was set back to the initial value (i.e., 0.005) after the completion 
of each cycle. During each cycle, the learning rate was annealed using step decay (the exact 
parameter values used are defined below). Setting back the learning rate to a high value (where 
high depends on the data sets being modelled) allows wider sampling of the loss landscape and 
to escape from local minima73,74 (Figure 1 and 2).  
 
In some cases, convergence was not achieved after the 3,000 epochs we used to train each 
network or started after few learning rate annealing cycles. We found that the loss on the 
validation set was either too high, indicating that no local minima were reached, or the 
predictions for the validation set were simply the mean pIC50 value of the instances in the 
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training data. Although the average error in prediction for the latter might be <1.2 pIC50 units 
(e.g., in cases where inactive data points abound), their generalization ability is limited. 
Therefore, these DNN were discarded and not used to generate Snapshot Ensembles. In cases 
where convergence was indeed achieved, we only kept snapshots with high predictive power; 
that is, leading to RMSE values on the validation set smaller than 1.2 pIC50 units. The training 
phase of each Snapshot Ensemble stopped once 100 snapshots with a validation RMSE < 1.2 
pIC50 units were taken. The 100 snapshots were used to predict the activity for both the 
validation and test sets. 
 
We defined three implementations of this scheme, each of them differing in (i) the number of 
epochs per cycle, (ii) epoch intervals at which snapshots were taken, and (iii) the step size in 
the learning rate decay function: 
 
- Snapshot Ensemble Lr Annealing 1: a snapshot was taken every 50 epochs, each 
cycle consisted of 50 epochs, and the learning rate was decreased by 40% every 10 
epochs 
- Snapshot Ensemble Lr Annealing 2: a snapshot was taken every 25 epochs, each 
cycle consisted of 250 epochs, and the learning rate was decreased by 40% every 10 
epochs.  
- Snapshot Ensemble Lr Annealing 3: a snapshot was taken every 50 epochs, each 
cycle consisted of 250 epochs, and the learning rate was decreased by 40% every 50 
epochs.  
 
- Random Forests (RF) 
RF models were trained using the python library scikit learn75. The default parameter values 
were used except for the number of trees, which was set to 100 given that higher values do not 
generally lead to increased performance when modelling bioactivity data37,76. Another reason to 
consider 100 trees was to ensure that the same number of base learners is used to generate 
RF and DNN ensembles. The same data set splits used to train DNN were used to train RF 
models. Specifically, RF models were trained on the training set (70% of the data), and the 
predictive power assessed on the test set (15%). 
 
Conformal Prediction 
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- Ensembles of DNN 
We describe below the main steps to generate conformal predictors using ensembles of DNN. 
For further theoretical details about the conformal prediction framework we refer the reader to 
31,32,36.  
The residuals and the standard deviation across a given DNN ensemble, be it a Snapshot 
Ensemble or a DNN Ensemble, served to generate a list of non-conformity values for the 
validation set as follows (Figure 1B): 
Equation	1:						 ∝-=	
|𝑦- − 𝑦23|
𝑒56
 
where 𝑦- is the i
th instance in the validation set, 𝑦23	is the average of the predicted activities for 
the ith instance across the ensemble, and 𝜎- is the standard deviation of the activity predictions 
across the ensemble. The resulting list of non-conformity scores, 𝛼, was sorted in increasing 
order, and the percentile corresponding to the CL considered was selected, e.g., 𝛼9: for the 80
th 
percentile. The validation residuals across the 20 runs of each learning strategy and data set 
combination were used to generate the list of non-conformity values. 
 
Normalizing the residuals is a widely used method to generate tighter predictions for instances 
that are easier to predict, as reflected by a lower variance across the ensemble36,77. We decided 
to use the natural exponential of the standard deviation across the ensemble to scale the 
residuals because previous studies showed that this approach slightly improves the efficiency of 
conformal predictors built on bioactivity data sets78. Basically, this scaling sets the upper value 
for the list of non-conformity values to be equal to the largest residual in the validation set, as 
the exponential converts low 𝜎- values to ~1. This is useful in practice to prevent large non-
conformity values. For instance, a very large non-conformity value would be obtained for a very 
biased prediction (i.e., large difference between the predicted and the true value), and 
displaying low variance (i.e., low variability across the base learners). This situation would occur 
in e.g., the presence of activity cliffs79. 
 
The standard deviation across the ensemble served to calculate confidence regions for 
individual instances in the test set as follows: 
 
Equation	2:						𝐶𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑐𝑒	𝑟𝑒𝑔𝑖𝑜𝑛 = 	𝑦E3 ± G𝑦H − 𝑦E3 G = 𝑦E3 ± (𝑒5J ∗ 	𝛼LM) 
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where 𝑦H is the j
th instance in the test set, 𝑦E3 	is the average of the predicted activities for the j
th 
instance across the ensemble, and 𝜎H is the standard deviation of the predicted activities across 
the ensemble. 
 
- Random Forests 
We also used Random Forests as a baseline comparison, in order to evaluate whether the 
conformal predictors generated using ensembles of DNNs lead to higher predictive power and 
tighter confidence intervals than the state of the art. In the case of RF, cross-conformal 
predictors were generated as previously reported35,80. In brief, RF models were trained on the 
training data using 10-fold cross validation. The cross-validation residuals and the standard 
deviation across the forest were used to calculate the list of non-conformity values37,78.  
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Results and Discussion 
We firstly evaluated the performance of the different ensemble strategies considered in this 
study. Overall, the performance of RF, DNN Ensembles, and the three Snapshot Ensembles we 
defined was comparable on the 24 data sets used in the current study (P > 0.05; Kruskal–Wallis 
test), with mean RMSE values on the test set across repetitions in the 0.6-0.9 pIC50 units range 
(Figure 3). These values are consistent with the expected errors in prediction for models built 
using heterogeneous IC50 data from ChEMBL56,57. We furthermore observed a variability of 0.05-
0.15 pIC50 units across the three Snapshot Ensembles for each data set (Figure 3). The 
comparable errors in prediction on the test set shows that Snapshot Ensembles performed on 
par with RF and DNN Ensembles. These results thus indicate that the deep learning 
architectures and parameter values we used to train the four types of DNN ensembles explored 
in this study are suitable to model these data sets. 
To examine the variability of the predictions across snapshots, we computed the correlation 
between the predictions on the test set for each pair of snapshots in the Snapshot Ensembles, 
and for the independently trained DNNs that form the Ensemble DNN (Figure 4 and S1-23). The 
test set predictions calculated by most of the DNN are less correlated in the Ensemble DNN 
(Figure 4A) than in the Snapshot Ensembles (Figure 4B-D). This is expected because the base 
learners in the Ensemble DNN are trained independently, whereas the snapshots are taken 
throughout the training phase of a single neural network. However, we note that the lowest 
Pearson correlation observed for the Ensemble DNN predictions ( i.e., ~0.92; Figure 3A; see 
Figures S1-23 for the remaining data sets) is also observed for the Snapshot Ensembles. In the 
case of Snapshot Ensembles, we also observe that the predictions on the test set are less 
correlated to the first annealing cycle (i.e., first snapshot) as the training phase advances. This 
is indicated in Figure 4B-D by the transition from green to brown across the x and y-axes (see 
also Figures S1-23). This indicates that during the training phase of Snapshot Ensembles 
multiple local minima are explored, each of them exhibiting different error profiles, thus helping 
to increase the diversity in the final ensemble. The predictions for the Snapshots taken 
throughout each learning rate annealing cycle (i.e, Snapshot Ensemble Lr Annealing 2-3), are 
more correlated than those extracted from other learning cycles, as evidenced by the dark 
green squares in the diagonal of Figure 4C-D. Note that this pattern is not observed for 
Snapshot Ensemble Lr Annealing 1 (Figure 4A), where each snapshot was taken at the end of 
 13 
each annealing cycle. Thus, the high predictive power of each snapshot on the test set, as well 
as the variability of the predictions across the ensembles, suggest that the snapshots in the 
Snapshot Ensembles converged to multiple high-quality local minima81. 
Next, we sought to investigate the validity of the conformal predictors generated using DNN 
Ensembles and Snapshot Ensembles. To this end, we computed the percentage of instances in 
the test set whose true values lie within the predicted confidence regions. For a conformal 
predictor to be valid, this fraction needs to be equal to or greater than the selected confidence 
level. The conformal predictors are valid for all data sets and learning strategies explored, as 
indicated by the high correlation between increasingly higher confidence levels and the 
percentage of confidence intervals encompassing the true bioactivity value (R2 > 0.99, P < 
0.001; Figures 5 and S24). Together, these results indicate that the four types of DNN-based 
ensembles considered here can be used to generate valid conformal predictors. 
The second critical aspect of a conformal predictor is the efficiency of the predicted confidence 
regions. Following the terminology used in the conformal prediction literature36, we use the term 
efficiency to refer to the average size of the predicted confidence intervals across models. The 
narrower the confidence intervals, the more efficient a conformal predictor is. Conformal 
predictors generating large intervals might be theoretically valid, but such wide errors bars 
would provide little practical information about which compounds to prioritize for further 
experimental testing in a real-world situation. Thus, we next compared the size of the 
confidence regions predicted by the conformal predictors based on RF, DNN Ensembles, and 
Snapshot Ensembles. 
The average size of the confidence regions is overall comparable across data sets for RF and 
DNN Ensemble models, and slightly higher for Snapshot Ensembles (Figure 6). The average 
size over the 20 repetitions of the confidence intervals is in the 0.8-1.2 pIC50 range for all 
learning strategies and data sets. These values are comparable to those previously obtained for 
other bioactivity data sets36,78, and are narrow enough to be practically useful for compound 
prioritization in most cases. Notably, the RF-based conformal predictors span a wider range of 
values, leading to confidence intervals larger than 6 pIC50 units in some cases (Figure 6). 
Although the spread of the distribution is larger for those Snapshot Ensembles with lower 
predictive power on the test set (Figure 3), at least one Snapshot Ensemble leads to a tighter 
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distribution for all data sets (Figure 6). This indicates that, although robust conformal predictors 
can be generated using Deep Confidence, the parameterization of the underlying networks 
needs to be optimized for each individual data set. 
The fact that the confidence intervals calculated with RF span a wider range of values (Figure 6) 
indicates that the predictions of the individual trees in the Forest are poorly correlated for some 
instances (i.e., high variance across the ensemble), and highly correlated for others (i.e., low 
variance). High variance across the ensemble leads to larger confidence intervals (Equation 2). 
In contrast, the confidence intervals for molecules for which the predictions across base 
learners are highly correlated, and hence display a lower variance, are tighter. Thus, lower 
variance across the ensemble should be reflected in more narrowly contained distributions of 
intervals sizes82. Analysis of the distributions of the standard deviation across the ensemble for 
the predictions on the test set confirms that the RF models display larger variance than DNN-
based ensembles, with mean values for RF around 3 times larger (Figure 7), thus explaining the 
differences observed in Figure 6. 
The validity of conformal predictors is guaranteed for the entire set of predictions, i.e., global 
validity36. However, the local validity, e.g., the validity of a conformal predictor if measured using 
data within a certain bioactivity range only, might not always be fulfilled. This is particularly 
important because the goal of most discovery projects is to find highly active compounds, and 
hence, guaranteeing that the error rates are correct for particular bioactivity ranges is of utmost 
importance. To further examine the local validity of the DNN-based conformal predictors, we 
calculated the error rate at confidence level 0.8 for each pIC50 unit bin, using the experimentally 
measured pIC50 values for binning the instances in the test set. We find that the error rate is 
around the expected value (0.20 in this case; i.e., 1 - 0.8) for most conformal predictors and 
data sets in the low micromolar and high nanomolar ranges (i.e., pIC50 of 5-7), although notable 
exceptions are present, e.g., data sets Caspase, COX-2, or HERG (Figures 8-9 and S25-26). 
Although not consistently, RF often shows a higher error rate for particular pIC50 bins (see e.g., 
data sets Ephrin and erbB1 in Figure 9). We note that the error rates are higher for regions with 
fewer instances, which correspond for most data sets to the high activity range. Future work will 
be needed to develop methods to guarantee the local validity for the high activity range, which is 
usually the range of interest and the one with fewer training instances. Together, these results 
indicate that the errors measured for DDN-based conformal predictors are more even than for 
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RF-based ones, as evidenced by the lower spread of the distributions of confidence intervals 
and, in some cases, the more evenly distributed error rates across pIC50 bins. 
Overall, we have shown here that it is possible to generate highly predictive models and valid 
conformal predictors using DNN Snapshot Ensembles. Of practical relevance to predictive 
modelling in drug discovery38, the derived confidence intervals display a smaller spread than 
that of RF-based conformal predictors. The performance for ensembles of independently trained 
DNN and Snapshot Ensembles is comparable. Thus, the framework proposed here is 
computationally efficient in that it just requires the training of a single neural network to generate 
confidence intervals. The parameter values used were found to work well on these data sets, 
given that model performance was in line with previously published analyses. However, further 
tuning of the deep learning architecture or the parameters would be advised for other learning 
tasks, data sets or compound descriptors13,18.  
We also stress that the potential of deep learning has not been fully exploited in this work due to 
the limited size of the data sets used. Although the performance of DNN ensembles and RF on 
these data sets is comparable, DNN will likely outperform RF on larger data sets23. It is precisely 
for the modelling of large data sets that the framework proposed here will prove more versatile 
to leverage both the increased predictive power of deep learning and the estimation of 
prediction reliability using conformal prediction, while requiring minimal extra computation. While 
the generation of snapshots during the training of a DNN requires no extra computation, we 
stress the fact that additional computation might be required to generate a Snapshot Ensemble 
if the network converges to high-quality local minimum before the number of epochs required to 
generate 100 snapshots is reached. This is however unlikely given that the global minimum is 
almost never reached in practice for deep architectures. We also note that the complexity of the 
loss landscape increases for deeper architectures83, and hence, sampling multiple local minima 
to generate a Snapshot Ensemble might require a more sophisticated learning rate annealing 
schedule in those cases. Future work will also be required to comprehensively evaluate whether 
the exhaustive sampling of local minima in the loss landscape leads to more efficient conformal 
predictors, as opposed to the sampling of a reduced set of these generating correlated 
predictions, or just sampling the vicinity of few local minima81. 
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Conclusions 
In this work we introduced Deep Confidence, a framework to compute valid and efficient 
confidence intervals for deep neural networks that requires no extra computational cost. 
Specifically, we have shown that snapshots taken throughout the training of a single neural 
network and corresponding to different local minima provide sufficient information to predict 
confidence regions that are narrower than those calculated with RF-based conformal predictors. 
Therefore, the framework proposed in this study has great potential to increase the application 
of deep neural architectures in early-stage drug discovery while also controlling for the reliability 
of individual predictions. 
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Figures 
Figure 1 Deep Confidence workflow. Illustration of the generation of a Snapshot Ensemble 
from the training of a single deep neural network (A), and the workflow proposed in this study to 
generate conformal predictors from Snapshot Ensembles (B). 
Figure 2  Loss on the validation set during the training of DNN using cyclical learning 
rate annealing. Evolution of the loss (shown in black, and corresponding to the RMSE for the 
observed against the predicted values for the validation set), best loss for each learning rate 
annealing cycle of 250 epochs (red), and the learning rate (shown in blue and annealed using 
step decay) for three representative data sets and across the first 1,500 epochs of the training 
phase. This learning rate annealing scheme corresponds to the learning strategy referred to in 
the text as Snapshot Ensemble Adjust Lr 3. It can be seen that the loss converges to a local 
minimum during each learning rate annealing cycle of 250 epochs, throughout which the 
learning rate is decreased by 40% every 50 epochs. It can be seen in (C) that the loss on the 
validation set decreases after multiple learning rate annealing cycles. 
Figure 3  Performance on the test set. Mean RMSE values (+/- standard deviation) on the test 
set across 20 runs for RF, DNN Ensembles, and Snapshot Ensembles are shown. Overall, the 
three types of Snapshot Ensembles considered showed high predictive power on the test data, 
indicating that the choice of parameter values is suitable for modelling these data sets. The 
color scheme used in this Figure is also used throughout subsequent figures in the manuscript. 
Figure 4 Analysis of the correlation of the base learner predictions on the test set for 
Ensemble DNN and Snapshot Ensembles (data set A2a). The pairwise correlation of the test 
set predictions was calculated for each pair of base learners forming the Ensemble DNN (A) 
and the three types of Snapshot Ensembles we defined (B-C). The correlation matrices were 
calculated using the predictions on the test set for the 20 repetitions. Overall, the test set 
predictions calculated by each DNN are less correlated in the Ensemble DNN than in the 
Snapshot Ensembles. This is expected given that the base DNN in the Ensemble DNN are 
independently trained. The dark green squares in the diagonal in C and D indicate that the 
predictions calculated with snapshots extracted from the same learning rate annealing cycle are 
more correlated than those extracted from other learning cycles. The transition from green to 
brown across the training phase observed for Snapshot Ensembles indicates that multiple local 
minima are explored in each annealing cycle throughout the training phase, and hence, the 
predictions on the test set are less correlated to the first annealing cycle as the training phase 
advances. A similar analysis for the other data sets is provided in Figures S1-23. 
Figure 5  Validity analysis. Each plot shows the correlation between the confidence level and 
the percentage of predictions whose true value is contained within the predicted intervals for the 
conformal predictors built on 4 representative data sets using RF (A), DNN Ensembles (B), and 
Snapshot Ensembles Adjust Lr 1-3 (C-E). It can be seen that valid models were obtained 
because the percentage of predictions whose true value lies within the predicted confidence 
region (1- error rate) strongly correlates with the confidence level. The validity analysis for the 
remaining data sets is provided in Figure S24. 
Figure 6  Analysis of the distribution of the confidence intervals. Each box plot shows the 
distribution of the size of the confidence intervals (in pIC50 units) calculated for the test set at 
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confidence level 80%. The predictions for the 20 runs are shown. Overall, it can be seen that 
the spread of the distributions for DNN-based methods is smaller, while the average size for the 
confidence regions is marginally higher, compared to RF. 
Figure 7  Ensemble variance analysis. Distributions of the standard deviation across the 
ensemble for the test set instances are shown across the 20 runs. Overall, it can be seen that 
the variance across the ensemble is significantly larger for RF as compared to DNN-based 
ensembles. This affects the spread of the distribution of intervals sizes, as shown in Figure 5. 
Figure 8  Analysis of the error rate across pIC50 bins. The error rates calculated for those 
instances in the test set with an observed pIC50 value in the range indicated in the x-axis at 
confidence level 80% are shown. The horizontal line indicates the expected error rate. 
According to the expected error rate, all points should be below the line. Points over the 
horizontal line indicate that the error rate is higher that the indicated by the chosen confidence 
level. The area of the dot shapes is proportional to the number of instances in each pIC50 bin. 
Overall, it can be seen that even if the global validity is kept (i.e., the error rate for all test set 
instances corresponds to the expected error rate for the selected confidence level; see Figure 
5), the validity across pIC50 bins varies considerably. The same analysis for the other data sets 
is provided in Figure 9. 
Figure 9  Analysis of the error rate across pIC50 bins for the remaining data sets. The error 
rates calculated for those instances in the test set with an observed pIC50 value in the range 
indicated in the x-axis at confidence level 80% are shown. The horizontal line indicates the 
expected error rate. See also Figure 8. 
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